Holen Sie sich die Stockscreener-App
0.97
15.43%
0.1297
Ovid Therapeutics Inc Aktie (OVID) Neueste Nachrichten
Ovid Therapeutics Transfers Stock to Nasdaq Capital Market - MSN
Analyzing Ovid Therapeutics Inc. with multi timeframe chartsAnalyst Upgrade & Community Verified Watchlist Alerts - Newser
What makes Ovid Therapeutics Inc. stock price move sharplyGap Down & Weekly High Return Forecasts - Newser
Ovid Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Tools to monitor Ovid Therapeutics Inc. recovery probabilityDividend Hike & Smart Money Movement Alerts - Newser
Ovid Therapeutics Plunges 11.42% on Q2 Loss, Pipeline Progress - AInvest
B.Riley Financial Initiates Ovid Therapeutics(OVID.US) With Buy Rating, Announces Target Price $3 - 富途牛牛
Ovid Therapeutics Reports Increased Revenue Amid Challenges - TipRanks
Ovid Therapeutics Q2 Earnings: Revenue Up, Net Loss Widens - AInvest
Ovid Therapeutics shares rise 34.92% intraday after reporting business updates and a $7.0 million royalty monetization agreement. - AInvest
Ovid Therapeutics Reports Q2 2025 Results: $38.3M Cash, $6.3M Revenue, Net Loss of $4.7M - AInvest
Ovid Therapeutics Surges 36.76%: What's Fueling the Biotech Breakout? - AInvest
Ovid Therapeutics earnings beat by $0.10, revenue topped estimates - Investing.com Canada
Ovid Therapeutics: Navigating the Maze of Rare Disease Innovation and Financial Constraints - AInvest
Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Ovid Therapeutics Reports Q2 2025 Financials, $7mln Royalty Deal, Q3 2025 Results Expected - AInvest
Ovid Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results | OVID Stock News - GuruFocus
Ovid Therapeutics Reports Business Updates and Second Quarter 20 - GuruFocus
Ovid Therapeutics Inc. SEC 10-Q Report - TradingView
Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results - GlobeNewswire
Lucid Capital Markets initiates Ovid Therapeutics stock with Buy rating By Investing.com - Investing.com Canada
Lucid Capital Markets initiates Ovid Therapeutics stock with Buy rating - Investing.com
Ovid Therapeutics (NASDAQ:OVID) Given Consensus Rating of “Buy” by Brokerages - Defense World
Will Ovid Therapeutics Inc. price bounce be sustainableSwing Entry Insight With Forecast Accuracy - Newser
Ovid Therapeutics (NASDAQ:OVID) Trading Up 7.9% – Here’s Why - Defense World
Is Ovid Therapeutics Inc. stock poised for growthFree Watchlist for Low Risk High Return - Newser
Ovid Therapeutics (OVID) to Release Quarterly Earnings on Tuesday - Defense World
Ovid Therapeutics OVID 2025Q2 Earnings Preview Upside Potential on Strategic Partnerships - AInvest
Ovid Therapeutics Maintains Buy Rating with $3.00 Price Target from B.Riley Financial Analyst Madison Elsaadi. - AInvest
How to track smart money flows in Ovid Therapeutics Inc.Value Investing Summary and Earnings Outlook - Newser
B.Riley assumes coverage on Ovid Therapeutics stock with Buy rating - Investing.com Australia
Has Ovid Therapeutics Inc. formed a bullish divergenceYield Curve Outlook and Long-Term Implication Summary - Newser
Short interest data insights for Ovid Therapeutics Inc.Earnings Impact and Stock Reaction Analysis - Newser
Ovid Therapeutics Inc. Stock Analysis and ForecastMarket-crushing profits - Jammu Links News
What are analysts’ price targets for Ovid Therapeutics Inc. in the next 12 monthsUnlock powerful trading signals and alerts - Jammu Links News
Is it the right time to buy Ovid Therapeutics Inc. stockOutstanding capital growth - Jammu Links News
Does Ovid Therapeutics Inc. stock perform well during market downturnsAchieve rapid wealth accumulation with smart picks - Jammu Links News
Is Ovid Therapeutics Inc. stock overvalued or undervaluedTremendous financial leverage - jammulinksnews.com
Should I hold or sell Ovid Therapeutics Inc. stock in 2025Invest smarter with actionable stock recommendations - Jammu Links News
What institutional investors are buying Ovid Therapeutics Inc. stockBuild a balanced portfolio for long-term success - Jammu Links News
How strong is Ovid Therapeutics Inc. company’s balance sheetMaximize gains with strategic stock entries - Jammu Links News
How does Ovid Therapeutics Inc. compare to its industry peersFree Wealth Planning Blueprint - Jammu Links News
Why is Ovid Therapeutics Inc. stock attracting strong analyst attentionSuperior stock growth - Jammu Links News
What is the dividend policy of Ovid Therapeutics Inc. stockUnrivaled growth potential - Jammu Links News
What are the technical indicators suggesting about Ovid Therapeutics Inc.Take advantage of unprecedented market momentum - Jammu Links News
Is Ovid Therapeutics Inc. Stock a Smart Buy in 2025 Investment Analysis Inside - Newser
What technical models suggest about Ovid Therapeutics Inc.’s comebackHigh Accuracy Trade Setup Identification - Newser
Ovid Therapeutics Inc (OVID) Stock: A Year of Market Movement, Down and Up - investchronicle.com
Multi asset correlation models including Ovid Therapeutics Inc.Free Secure Capital Picks With Upside Potential - Newser
Combining price and volume data for Ovid Therapeutics Inc.Buy Strategy with Smart Exit Timing - Newser
Identifying reversal signals in Ovid Therapeutics Inc.Low Volatility Stock Analysis With Confidence - Newser
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):